Skip to content

Intramyocardial Haemorrhage in Patients With Primary STEMI

Clinical Trial Appreciating Intramyocardial Haemorrhage in Patients With Primary STEMI and Different Reperfusion Strategies (Pharmaco Invasive Strategy and Primary PCI)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03677466
Acronym
HaemInCor
Enrollment
60
Registered
2018-09-19
Start date
2018-01-25
Completion date
2019-03-20
Last updated
2019-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, STEMI, Myocardial Necrosis, Myocardial Injury

Keywords

Intramyocardial haemorrhage, Myocardial Infarction, ST Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention, Pharmaco invasive strategy, Fibrinolytic therapy, Global longitudinal strain, Myocardial Necrosis, Coronary Artery Disease

Brief summary

The purpose of the study is to assess the frequency and intensity of intramyocardial haemorrhage in patients with primary STEMI and different reperfusion strategies.

Detailed description

The study non-randomized, opened, controlled. In half of patients despite on carried in-time reperfusion therapy intramyocardial haemorrhage determined after a long-term period of severe ischemia. Earlier, definition of intramyocardial haemorrhage was possible only by autopsy. Nowaday, cardiac contrast MRI is the best diagnostic method, which allows to assess the regional and global function of the LV, structural changes in myocardial tissue and also in T2 mode it became assessable to reveal intramyocardial haemorrhage. Taking into account the results of previous researches, it can be concluded that the intramyocardial haemorrhage was determined in half of patients with primary PCI \[1\]. An influence of fibrinolytic therapy to the intramyocardial haemorrhage was conducted in small group of patients in one trial, and therefore further data will be actual and useful \[2\]. It is planned to study 60 patients with primary STEMI using standard therapy. The patients will be divided into 2 groups. Patients of the 1st group will be treated by pharmaco-invasive strategy. The 2nd group will be treated by primary PCI. Patients in all groups after reperfusion strategies will be conducted cardiac contrast MRI for detection intramyocardial haemorrhage within 2 days onset. At day 7 and through 3 months, the clinical condition of the patients will be assessed and cardiac ultrasound will be performed for the evaluation of myocardial contractile function and 2D global longitudinal strain. Also, the incidence rate of secondary endpoints will be evaluated.

Interventions

DRUGPharmaco-invasive strategy

Patient with primary STEMI will received standard doses of fibrinolytics with following PCI. After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.

PROCEDUREPrimary PCI

After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.

Sponsors

Tomsk National Research Medical Center of the Russian Academy of Sciences
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years at time of randomization (18 years and older); * Acute myocardial infarction; * Reperfusion of the infarct-related coronary artery in terms within 12 h of symptom onset; * Written the informed consent to participate in research;

Exclusion criteria

* Inability to obtain informed consent; * Patients previously undergone endovascular / surgical revascularization of coronary artery; * Severe comorbidity; * History of myocardial infarction; * History of intracranial haemorrhage; * Pulmonary edema, cardiogenic shock; * Creatinine clearance \<30 mL/min or dialysis; * Unable to undergo or contra-indications for MRI; * Allergy for contrast agent; * Indication or use of oral anticoagulant therapy; * Major bleedind; * Atrio-ventricular block II and III degree; * Active gastroduodenal ulcer; * Aortic dissection; * Acute psychotic disorders

Design outcomes

Primary

MeasureTime frameDescription
Intramyocardial haemorrhage in primary STEMI measure2 daysIntramyocardial haemorrhage (%) in patients with primary STEMI as assessed by cardiac magnetic resonance imaging 2 days after reperfusion

Secondary

MeasureTime frameDescription
Global Longitudinal Strain3 months (with intermediate measurement at day 7 after reperfusion)Global Longitudinal Strain (%) measured with echocardiography 7 days and 3 months after reperfusion strategies
Recurrent myocardial infarction measure3 monthsIncidence of recurrent myocardial infarction (%) 3 months after STEMI
Heart failure incidence measure3 monthsIncidence of heart failure (%) 3 months after STEMI
Left ventricular ejection fraction (LVEF) recovery measure3 months (with intermediate measurement at day 7 after reperfusion)Left ventricular ejection fraction (LVEF) (%) recovery measured with echocardiography 7 days and 3 months after reperfusion strategies
Mortality measure3 monthsMortality rate (%) 3 months after STEMI
Major bleeding incidence measure3 monthsIncidence of major bleeding (%) 3 months after STEMI
Stroke incidence measure3 monthsIncidence of stroke (%) 3 months after STEMI

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026